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Abstract: Anderson-Fabry disease (AFD) is an X-linked storage disorder caused by a deﬁ  ciency 
of the lysosomal hydrolase a-galactosidase A (AGAL) and the resultant accumulation of its 
glycosphingolipid substrate (Gb3) in several tissue types. Major morbidity and reduced life 
expectancy among affected individuals are a consequence of renal, cardiac and cerebrovascular 
involvement. Symptomatic males and females with AFD have been described, although the onset 
of clinical manifestations may be delayed and more variable among the latter patient group, partly 
attributed to lyonization. Agalsidase alfa (ReplagalTM) is a recombinant formulation of human 
AGAL which has been demonstrated to modify the course of AFD in treated patients. Factors 
that may inﬂ  uence clinical outcomes include disease stage at the point of treatment initiation 
and antibody formation. There is incomplete understanding of AFD pathophysiology. Early 
diagnosis and timely intervention may be essential. The use of adjunctive therapies, directed at 
risk reduction (eg, aspirin for stroke prophylaxis), require careful scrutiny, but such agents are 
likely to be vital components of a comprehensive approach to patient care. Long-term studies 
may clarify the optimal dose and frequency of enzyme administration. Meanwhile, budding 
strategies such as chaperone-mediated enzyme enhancement may offer the potential for an 
alternative or multimodality approach to the management of AFD.
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Background
Anderson-Fabry disease (AFD) is a multi-systemic disorder, associated with major 
renal, cardiac and cerebrovascular complications; consequent to the progressive 
deposition of an incompletely metabolized substrate (Gb3) in multiple cell types, and 
attendant mechanisms of tissue injury that remain to be more fully deﬁ  ned (Clarke 
2007). Alterations in vascular reactivity and a propensity for thrombo-embolic disease 
are believed to play a role in the increased risk for particular problems, such as stroke 
(Moore et al 2007). Renal and cardiac failure represent major sources of morbidity, 
and likely account for the reduced survival among affected males and females (wherein 
median age of death is 50–57 and 70–72 years, respectively) (MacDermot et al 2001a, 
2001b). In conjunction, pain crises, acroparesthesia, hearing loss and gastrointestinal 
problems lead to signiﬁ  cant reduction in patients’ health-related quality of life (Gold 
et al 2002).
The series of events that have led to development of treatment directed at the 
underlying biochemical basis of AFD include: (1) elucidation of the causal enzyme 
deﬁ  ciency (a-galactosidase A (AGAL)); (2) characterization of the relevant recep-
tor-mediated endocytic pathway (mannose-6-phosphate [M6P] receptor) and thus, 
enabling intracellular uptake of the intravenously administered therapeutic protein; 
and (3) over-expression of the recombinant form of AGAL in a mammalian cell line 
with the requisite glycosylation pattern for delivery to the appropriate cell types (see 
Pastores 2003).Biologics: Targets & Therapy 2007:1(3) 292
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The incidence of AFD is about 0.85 per 100,000, 
although recent studies suggest that the condition may be 
missed, particularly among patient populations at high risk 
(eg, patients with ESRD on dialysis, and young individuals 
with cyrptogeneic stroke) (Ichinose et al 2005; Rolfs et al 
2005; Tanaka et al 2005).
As an “orphan disorder” the development of treatment for 
AFD qualiﬁ  ed for fast-track approval, with several incentives 
provided to the manufacturers to stimulate industrial drug 
development (Pastores 2003). The current review examines 
the clinical experience with agalsidase alfa which supports 
the safety and efﬁ  cacy of enzyme therapy for AFD.
Agalsidase alfa and special 
considerations
The recombinant enzyme agalsidase alfa (ReplagalTM, Shire 
Human Genetic Therapies (HGT), Inc., Cambridge, MA, 
USA) is produced in a cultured human cell line following 
the activation of the relevant encoding gene. It is currently 
approved for the treatment of AFD in 38 countries, but not 
in the United States.
Attributes
Shire HGT’s manufacturing process ensures an appropriate 
and species-speciﬁ  c post-translational modiﬁ  cation of the 
primary amino-acid sequence, a factor that is critical in the 
targeted delivery of the therapeutic enzyme to the cellular 
sites of substrate storage (van de Weert et al 2005). Further-
more, intrinsic glycosylation and other differences between 
the recombinant formulation and the native (endogenous, 
non-mutant) enzyme may be a factor in the development of 
antibodies against the intravenously administered protein 
(Baker and Jones 2007).
Pharmacokinetics and pharmacodynamics
There is limited information on tissue distribution and 
enzyme half-life following the administration of agalsidase 
alfa to humans. Less than 1% of the maximal plasma con-
centration of agalsidase alfa is detectable 8 hours after infu-
sion (data on ﬁ  le, Shire HGT), and the intracellular half-life 
of the enzyme is estimated to be 24–48 hours (Schiffmann 
et al 2000).
Recently, detailed information was published on the 
relative tissue and cellular distribution of agalsidase alfa in a 
mouse knockout model of AFD (Murray et al 2007). Speciﬁ  c 
immunostaining for the recombinant enzyme was found in 
the liver, kidney, heart, testes, adrenal gland, spleen and bone 
marrow. The patterns of cellular uptake were varied; from 
enzyme presence in parenchymal as well as endothelial cells 
in the liver and the adrenal glands, to selective uptake into 
certain cell types such as in the kidney and spleen, to the 
heart and bone marrow where immunostaining was observed 
only in the vascular endothelial cells. AGAL-speciﬁ  c activity 
in tissue homogenates matched the relative extent of tissue 
distribution.
The mechanism of the differential uptake of agalsidase 
alfa in the different organs of the mouse model, as in humans, 
is likely complex, and only partly explained by the distribution 
and density of M6P receptors. Furthermore, tissue distribution 
in these experiments did not did not correlate directly with 
the relative organ blood ﬂ  ows or the presence or absence of 
fenestrated capillaries in various organs (Murray et al 2007). 
However, it should be noted that these ﬁ  ndings resulted from 
a single intravenous injection of the enzyme and that repeated 
administration, as occurs in the clinical setting, may lead to a 
different proﬁ  le. Moreover, the mouse model (while exhib-
iting the biochemical features of AFD) does not follow the 
characteristic course of disease seen in human patients. This 
has limited its utility in establishing therapeutic guidelines, 
with studies in the mouse having found their greatest utility 
in establishing pre-clinical “proof of concept” and the effects 
of enzyme therapy on substrate deposits.
The issue of targeted enzyme delivery to cellular sites 
of pathology is an important one. Currently, there are two 
enzyme formulations given to patients with AFD (Pastores 
and Thadhani 2002). As experiments in the mouse model for 
the two recombinant enzymes were conducted separately, it is 
not certain whether the use of an identical treatment protocol 
would reveal any differences in tissue uptake between the two 
drugs that may be relevant clinically. Anyhow, these inves-
tigations appear to have established a dose-response rela-
tionship; ie, tissue clearance is greater when using a higher 
dose of enzyme. However, as the correlation between tissue 
substrate accumulation and organ dysfunction is uncertain, 
the advantages of using a higher treatment dose remains to 
be determined. Whatever the case may be enzyme therapy 
regimens must be chosen judiciously and ultimately decisions 
regarding treatment should based on clinical outcome.
Should delivery to certain compartments be a limiting 
factor, one approach that has been suggested as a means 
to enhance tissue distribution of AGAL might be to add a 
protein transduction domain such as the 11-amino acid TAT 
peptide, as has been done with ß-galactosidase (a lysosomal 
enzyme deﬁ  cient in GM1-gangliosidosis) (Cai et al 2006).
The pharmacokinetics of agalsidase alfa in humans has 
been examined in a study involving 18 adult male AFD patients Biologics: Targets & Therapy 2007:1(3) 293
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naïve to enzyme replacement therapy; randomized to one of 
ﬁ  ve regimens: 0.1, 0.2, or 0.4 mg/kg weekly, and 0.2 or 0.4 
mg/kg every other week (Clarke et al 2007). The observed 
mean half-life was 56–76 minutes, and the mean volume of 
distribution at steady state was 17%–18% of body weight. No 
signiﬁ  cant association was noted between dose and half-life, 
clearance, or volume of distribution at steady state. The AUC 
was linearly proportional to dose from 0.1–0.4 mg/kg. Plasma 
Gb3 (average at baseline 9.12 ± 2.61 nmol/mL) declined by 
50% after 10 weeks of treatment, with no statistically sig-
niﬁ  cant differences between enzyme therapy regimens. It is 
interesting that the circulating half-life of the recombinant 
enzyme is signiﬁ  cantly longer than that for the therapeutic 
protein (imiglucerase) administered to patients with Gaucher 
disease. Whether the presence of a neutral pH in plasma and the 
potential for processing of the exogeneous enzyme during its 
transit to target organs may adversely affect the concentration 
of functional enzyme in the various tissues is not known.
As nearly all classically affected males with AFD expe-
rience kidney dysfunction, the pharmacokinetics (PK) of 
agalsidase alfa was also examined in patient with progres-
sion to end-stage renal disease (ESRD). Twenty-two AFD 
patients (20 men and 2 women) receiving dialysis or who 
had a history of kidney transplantation were treated with 
agalsidase alfa in an open label setting using the same dosing 
regimen given to patients without ESRD (0.2 mg/kg every 
other week) (Pastores et al 2007). A typical biphasic plasma 
elimination proﬁ  le was seen in both dialysis and transplant 
patients, similar to that observed in 18 non-ESRD patients 
with AFD. Calculated PK parameters were similar among 
these three patient groups. In the male patients, plasma Gb3 
level declined by 43% after 6 months (p  0.001).
The proportion of infused enzyme delivered to the various 
organs, the fraction that remains active within these different 
compartments, and the length of activity are unknown. It is 
possible that there are factors in plasma that may adversely 
affect the circulating enzyme whose optimal activity is within 
the acidiﬁ  ed environment of the lysosome. The latter may 
include antibodies which may facilitate the rapid clearance of 
the exogeneous enzyme and\or neutralize its function. Addi-
tionally, the formation of antibody-antigen complexes may 
result in altered targeting to other cells such as phagocytes. 
Non-speciﬁ  c enzyme uptake by cells without evident Gb3 
storage is unlikely to reduce systemic substrate burden.
Disease-modifying effects
Several studies, including a placebo-controlled clinical trial 
and the analyses of data derived from an observational survey 
(FOS), have demonstrated the beneﬁ  cial effects of agalsidase 
alfa. (FOS stands for Fabry Outcome Survey, a collabora-
tive effort established to pool data (initially from European 
clinics) on the natural history of AFD and the long-term 
efﬁ  cacy and safety of treatment (Mehta et al 2004).)
Various reports have noted small reductions in the inci-
dence and severity of neuropathic pain and gastrointestinal 
symptoms, and improvements in the perception threshold for 
warm and cold sensation (Altarescu et al 2001; Schiffmann 
et al 2001). Additionally, increased sweating and slow-
ing of the progression of renal disease in adult male AFD 
patients have also been documented (Schiffmann et al 2003). 
Furthermore, treatment has also been shown to lead to a 
reduction in left ventricular mass; although it is not certain 
whether this ﬁ  nding translates to a reduction in the incidence 
of cardiac-related events (eg, arrhythmias, myocardial 
infarction) (Hughes et al 2007). There is uncertainty about 
whether enzyme therapy results in a reduction in the inci-
dence of stroke. During a 4- to 4.5-year period of follow-up 
for the original NIH cohort which enrolled 26 hemizygous 
males, four patients suffered a cerebrovascular accident or a 
transient ischemic attack, one patient suffered a myocardial 
infarction and required a coronary bypass, and another patient 
underwent a coronary angioplasty (Schiffmann et al 2006). 
The latter observations underscore the need to incorporate 
adjunctive measures for secondary and probably primary 
prevention (Close and Elliott 2007).
All told, these observations have led to the current 
clinical impression that enzyme therapy for AFD appears 
to positively influence the patients’ health-related quality 
of life (QoL) and ameliorates the natural course of 
disease. However, its influence on survival and on the 
incidence and severity of disabling disease complications 
(and the associated utilization of resources, such as dialy-
sis, the use of an implantable pacemaker or defibrillator) 
remains to be established.
It should also be pointed out that the quality of most of the 
publications has been viewed as less than optimal, primarily 
because most focused on surrogate endpoints and not on the 
assessment of clinical endpoints (Lidove et al 2007).
It is likely that enzyme therapy for AFD is most efﬁ  ca-
cious when administered prior to established disease changes 
(eg, glomerulosclerosis, myocardial ﬁ  brosis). As progressive 
disease expression is partly inﬂ  uenced by age, there has 
been interest in examining the effects of treatment in chil-
dren. Although it is too soon to ascertain whether the use of 
agalsidase alfa in children eliminates the risk of major organ 
failure, or delays the inception of renal insufﬁ  ciency and Biologics: Targets & Therapy 2007:1(3) 294
Pastores
other problems, treatment is well tolerated and, in the short 
term, appears to improve autonomic function, decrease pain 
and improve pain-related QoL (Ries et al 2006; Ramaswami 
et al 2007).
Enzyme therapy regimens
Symptomatic patients with AFD are conventionally treated 
with 0.2 mg/kg of agalsidase alfa q 2 weeks. The current 
regimen that is used for most AFD patients may have been 
chosen, as the bi-monthly infusion schedule had been shown 
to be adequate for another glycosphingolipid (GSL) disorder 
(Gaucher disease) and is deemed to be a convenient schedule 
by most. Almost all of the current outcome data on agalsidase 
alfa is from patients treated at 0.2 mg/kg every other week 
(EOW). On this regimen, patients with stage I or II chronic 
kidney disease (CKD) appear to show stabilization of their 
glomerular ﬁ  ltration rate (GFR); whereas patients with stage 
III CKD (30–59 mL/min/1.73 m2) demonstrate a slower rate 
of decline in renal function (about 5.2 mL/min/1.73 m2/year), 
when compared with a historical control of untreated AFD 
male patients (12 mL/min/1.73 m2) (Schiffmann et al 2006). 
Thus, treatment beneﬁ  t appeared to occur mostly in patients 
with a relatively preserved baseline glomerular ﬁ  ltration rate 
(GFR) (60 mL/min/1.73 m2).
In a study of adult male AFD patients (N = 11) on 2–4 
years of this regimen and who demonstrated a continuing 
decline in renal function (specifically, of eGFR of 5 
mL/min per 1.73 m2/year), an improved slope of decline 
was noted with weekly administration on the same dosage 
per infusion (Schiffmann et al 2007). Before switching to 
weekly dosing, eGFR was 53.7 ± 6.3 mL/min per 1.73 m2 
(mean ± SEM), and mean rate of change in eGFR was −8.0 ± 
0.8 mL/min per 1.73 m2/year. During the 24-month follow-
up period on the weekly dosing, the mean rate of change 
in eGFR was observed to slow to −3.3 ± 1.4 mL/min/1.73 
m2/year (p = 0.01 vs EOW). Essentially only two patients 
failed to improve their eGFR slope. A multiple regression 
model confirmed that the weekly infusion regimen was 
the strongest explanatory variable for the change in eGFR 
(p = 0.0008), with a weaker contribution from the concomitant 
use of angiotensin converting enzyme inhibitors/angiotensin 
receptor blockers (p = 0.02). No information on kidney histol-
ogy was available to ascertain the extent of renal structural 
abnormalities (eg, focal and global glomerular sclerosis, 
tubular atrophy, interstitial ﬁ  brosis) and its “chronicity”. 
Proteinuria is an important risk factor for progression of 
kidney involvement in a number of disorders, and may be 
a useful factor to consider in AFD patients. Unfortunately, 
at the currently approved dose/frequency of administration 
enzyme therapy does not have a signiﬁ  cant impact on urinary 
protein excretion (Warnock 2007).
To some extent it appears logical to tailor the enzyme 
therapy regimen to substrate ﬂ  ux (and ensure clearance of pre-
existing substrate and the prevention of its re-accumulation), 
assuming that the Gb3 is the major pathogenic factor. On the 
other hand, neither the amount nor the type of glomerular Gb3 
deposition has been correlated with degree of renal dysfunc-
tion, or with functional improvement among treated patients 
(Warnock 2007). Earlier studies, which were undertaken prior 
to the introduction of more sophisticated quantitative assess-
ments (as by tandem MS), indicated turnover times for plasma 
Gb3 of about 4–8 days, with a turnover rate of 1–6 μmol/day 
(Vance et al 1975). Given the relatively short intracellular 
half-life of the enzyme, it is possible that prior to the next 
infusion (when given at 2 week intervals), ‘susceptible cells’ 
may be left “unprotected”. This hypothesis is in agreement 
with clinical report given by some patients who note a return 
of some of their AFD symptoms such as neuropathic pain and 
the lack of sweating as well as loss of energy or vitality after 
the ﬁ  rst post-infusion week. However, these observations 
require further study, and the issue of optimal dose\frequency 
of administration remains to be resolved.
Until lately, there has been no direct assessment (ie, a 
head-to-head clinical trial) of the two available enzyme 
formulations. Recently, the results of a comparative trial 
involving 34 AFD patients treated with either agalsidase 
alfa or agalsidase beta at an equal dose of 0.2 mg/kg every 
2 weeks were published (Vedder et al 2007). No signiﬁ  cant 
difference was found in reduction of left ventricular mass 
(the primary endpoint) or changes in other disease parameters 
(ie, glomerular ﬁ  ltration rate, pain, anti-agalsidase antibodies, 
and plasma and urine Gb3 levels), after 12 and 24 months of 
treatment with either enzyme formulation. Treatment failure, 
which appeared to be related to age and severe pre-treatment 
disease, occurred frequently in both treatment groups. More-
over, further progression of disease could not be prevented 
after a switch to 1.0 mg/kg of agalsidase beta.
Safety and tolerability concerns
Intravenous agalsidase alfa is reasonably well tolerated, 
with reported infusion reaction of about 10% and mostly 
consisting of fever and rigors, of mild to moderate intensity 
and transient. IgG antibodies have been noted in about 55% 
of treated patients, but none have developed IgE antibodies 
and there are no reports of an anaphylactic reaction to the 
infused enzyme. Reactions were mitigated by reducing the Biologics: Targets & Therapy 2007:1(3) 295
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rate of infusion and/or with the administration of appropriate 
premedications (eg, antihistamines, corticosteroids). The 
short infusion time for agalsidase alfa and the limited num-
ber and transient nature of adverse events that have been 
observed in treated patients have prompted consideration of 
home-based infusions.
Sero-conversion: determinants
and clinical implications
The use of recombinant proteins as therapeutics is fre-
quently associated with the generation of antibodies, which 
may impact clinical efﬁ  cacy. Many factors inﬂ  uence the 
immunogenicity of a protein, including structural properties 
(eg, sequence variation and glycosylation), and dose and 
length of treatment (Schellekens 2005).
Alongside the factors noted above that may determine 
a protein’s antigenicity, the patient’s CRIM (cross-reacting 
immunologic material)-status is also an important consider-
ation. This issue is particularly relevant among individuals 
with the “classic” phenotype in whom a deleterious mutation 
results in the generation of a severely truncated or defective 
protein that is rapidly cleared. In these cases, particularly 
among hemizygote males, the recombinant enzyme formula-
tion may be seen a “foreign” protein leading to the induction 
of antibody formation. As the enzyme is encoded by a gene on 
the X chromosome (at Xq22), affected males only produce a 
mutant gene product, whereas carrier (heterozygous) females 
may produce a normal gene product in various cell types; the 
extent of which is dependent on the pattern of lyonization. 
(The latter partly explains the difﬁ  culty of identifying female 
carriers, based on measuring residual enzyme activity in 
plasma and leukocytes; as the value obtained (in up to 20% 
of cases) may overlap with that encountered in the general 
healthy population. The presence of residual enzyme activity 
among symptomatic females may be the basis for their attenu-
ated phenotype and the greater variability in clinical expres-
sion when compared to that seen among affected males. A 
later disease onset and relatively milder clinical disease course 
are also found among affected male patients with missense 
mutations associated with residual enzyme activity.)
In vitro studies have revealed that antibodies that develop 
in patients on one of the two enzyme formulations cross-react 
with the other and result in the neutralization of AGAL activ-
ity. In a study involving a subgroup of patients (n = 8) with 
a persistent IgG antibody response, mean urine Gb3 levels 
were observed to rise, reaching mean baseline (Linthorst et al 
2004). Further studies are required to ascertain the long-term 
implications of antibody formation, although it is reassuring 
to note that titers have been noted to decline in some patients 
receiving on-going treatment.
Home infusion
The protracted requirement for regular intravenous infusion 
of the recombinant enzyme, the costs related to a clinic- or 
hospital-based administration, and the potential interference 
with lifestyle and other encumbrance on the patient have 
prompted consideration of home-based therapy. Fortunately, 
the safety proﬁ  le of agalsidase alfa and its ease of adminis-
tration over a minimum period of 40 minutes have enabled 
this approach.
In a single center study involving twenty-two patients 
whose infusions had been transitioned to the home setting, a 
total of 1528 treatments were administered (range of 42–73 
infusions per patient) (Schiffmann et al 2006). No additional 
safety concerns were raised by administration of agalsidase 
alfa in the home setting by a visiting nurse. Speciﬁ  cally, no 
patient experienced the new onset of infusion reactions after 
switching to home therapy.
Palliative measures and adjunctive 
therapies
As a large proportion of AFD patients currently on enzyme 
therapy are adults, with a lifetime of tissue Gb3 storage and 
varying degrees of renal, cardiac, and cerebrovascular dys-
function, there is a continuing need for palliative measures 
and adjunctive therapies to optimize clinical outcome.
The rationale for the use of adjunctive therapies is based 
on their conventional or demonstrated value in modulating 
risks associated with other chronic conditions, such as hyper-
tension and stroke (Berthiaume et al 2007; Kikano and Brown 
2007). These measures may include anti-platelet agents (eg, 
aspirin or clopidogrel) to reduce the incidence of transient 
ischemic attacks and stroke. Other therapies that have been 
suggested include the use of angiotensin converting enzyme 
(ACE) inhibitors and angiotensin receptor blockers (sartans) 
for patients with proteinuria (30 mg albumin/g creatinine), 
the regulation of blood pressure and statins (Ferrari 2007). 
Statins may improve renal and cardiac outcomes in AFD 
by decreasing circulating levels of low-density lipoproteins 
(LDL), improving endothelial function, or decreasing pat-
terns of LDL oxidation (Campese and Park 2007). Inves-
tigations of disease mechanisms in AFD are essential, and 
may clarify the role of adjunctive therapies in the overall 
management of affected individuals.
Among palliative approaches, the introduction of renal 
replacement therapy (ie, dialysis and renal transplant) for Biologics: Targets & Therapy 2007:1(3) 296
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ESRD during the period preceding enzyme therapy resulted 
in an increased survival by a decade or more (Sessa et al 
2004). A few patients have had implantable pacemakers and 
deﬁ  brillators for bradycardia and arrhythmias, respectively; 
but the number of lives saved through these measures has not 
been as closely examined (Shah et al 2005). It is hoped the 
availability of enzyme therapy and greater use of adjunctive 
therapies will at least delay, if not prevent the onset of major 
organ failure. These developments would offset the acquisi-
tion costs of agalsidase alfa, while signiﬁ  cantly improving 
patient quality of life.
Surrogate markers and measuring 
therapeutic response
In the phase III pivotal study, agalsidase alfa treatment 
resulted in a 54% reduction in plasma Gb3 levels from base-
line, as measured by HPLC. In urine sediment, the magnitude 
of reduction in Gb3 was about 50% (Schiffmann et al 2001). 
A clinical endpoint (ie improvement in neuropathic pain, as 
measured with the Brief Pain Inventory) was chosen as the 
primary outcome variable. Although agalsidase alfa was 
shown to signiﬁ  cantly reduce “pain at its worst”, “overall 
pain severity”, and “pain-related quality of life” when 
compared to placebo, several concerns (eg, inconsistencies 
in reporting of pain medication usage, disparity in baseline 
pain scores between treatment groups) were raised during 
the process of regulatory review by the US Food and Drug 
Administration regarding the interpretation of study ﬁ  ndings 
(see Pastores 2004).
A decline in plasma levels and endothelial cell storage 
of Gb3, the primary substrate of AGAL, supported the con-
ditional approval of agalsidase beta (Fabrazyme, Genzyme 
Corp, Boston, MA, USA) (Eng et al 2001). This situation 
for an ‘orphan disorder’ was justiﬁ  ed based on the outcome 
of preclinical studies in the AFD mouse model, which 
established delivery of the recombinant enzyme to and the 
clearance of stored substrate in several target organs, such 
as the liver, heart and kidneys. Unfortunately, the validity of 
Gb3 as a surrogate marker of disease burden and its clinical 
utility had not been established beforehand, and currently 
there is debate about its usefulness in the serial evaluation 
of treated and untreated AFD patients.
A recent study involving 96 patients with AFD revealed 
a limited relationship between plasma Gb3 and various 
disease manifestations, and that individual symptoms did 
not correlate with either elevated urinary or plasma Gb3 
levels (Vedder et al 2007). Additionally, a separate report 
noted that despite the virtual absence of storage material in 
plasma and skin vascular endothelial cells, a wide spectrum 
of clinical abnormalities was seen in a group of carrier women 
(N = 61) (Gupta et al 2005). In the latter study, all patients 
had normal plasma Gb3 levels and only a single patient had 
visible storage material in the superﬁ  cial dermal vascular 
endothelial cells. Yet, cardiac, renal, or cerebrovascular 
abnormalities were documented in 52/57 patients (91%) 
(Gupta et al 2005). Moreover, no studies have reported on 
the correlation between degree of reduction in plasma or 
cellular Gb3 levels and clinical beneﬁ  t.
The source of Gb3 found in plasma is not known, and 
may reﬂ  ect a surplus from the cellular turnover of membranes 
from a variety of organs and newly synthesized substrate 
in transit. It is possible that the detrimental health effects 
of Gb3 may be a consequence primarily of its intracellular 
storage; resulting in a disruption of GSL metabolism and 
the activation of additional complex cellular abnormalities. 
Indeed, a recent study suggested the presence of a potentially 
toxic factor (a growth-promoting substance) present in the 
plasma of AFD patients may stimulate the proliferation of 
vascular smooth muscle cells and cardiomyocytes (based on 
in vitro studies in the rat and mouse) (Barbey et al 2006). 
The signiﬁ  cance of parallel or downstream pathologic events 
within AGAL deﬁ  cient cells is underscored by the lack 
of perfect concordance between organ pathology and the 
amount of tissue Gb3 storage. This is evident when consider-
ing that in a severely hypertrophic heart of an AFD patient, 
Gb3 accounted for only about 0.3% of the total weight 
(Elleder et al 1990). In addition, systolic dysfunction or a 
severe restrictive hemodynamic ﬁ  lling pattern is not usually 
encountered in these cases until later in the course of disease. 
Interestingly, an increase in common carotid artery intima-
media thickness has been noted among males and females 
with AFD, suggesting a congruence of disease mechanisms 
that is independent of the level of residual plasma AGAL 
activity (characteristic of most female carriers and some 
male patients with the “variant” phenotype). Additionally, 
in male patients with AFD receiving enzyme therapy there 
was no signiﬁ  cant improvement of coronary microvascular 
function, in spite of Gb3 clearance from endothelial cells 
(Barbey et al 2006). Failure to fully correct the microvascu-
lar dysfunction in AFD despite enzyme therapy may partly 
explain the persistent risk for stroke, even with reversal of 
the exaggerated cerebrovascular dynamics.
Thus, besides cardiac Gb3 storage there must be other 
mechanisms that play a contributory role and account 
for the observed myocardial remodeling. A recent study 
involving 29 adult AFD patients, revealed the presence of Biologics: Targets & Therapy 2007:1(3) 297
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abnormal extracellular matrix turnover (based on elevated 
serum MMP-9 levels), which was negatively correlated with 
endocardial and mid-wall fractional shortening (Shah et al 
2007). The distribution of ﬁ  brosis in the mid-myocardial 
and left ventricular free wall puts it beyond the reach of 
conventional biopsy. On the other hand, cardiac magnetic 
resonance imaging may be useful for the characterization 
of myocardial tissue in AFD, and it may be important to 
establish the presence and extent of myocardial ﬁ  brosis and 
corresponding functional changes prior to therapy (Imbriaco 
et al 2007).
It should be noted that the state of affairs may be entirely 
different with respect to the brain and kidneys; wherein 
intracellular Gb3 may exert a more direct injurious effect. 
Clearly, these are issues that require further investigation. 
Recently, a systems biology approach has been undertaken 
to demonstrate multiple and complex parallel cellular abnor-
malities in AFD. The observed abnormalities may be used 
to identify potential surrogate markers that can be used as a 
measure of total body or organ-speciﬁ  c burden of disease, 
which may also be useful in monitoring response to enzyme 
therapy (Moore et al 2007).
Albuminuria is a cardiovascular and renal risk factor in 
patients with comorbid conditions (eg, diabetes and hyper-
tension); with relative risk shown to increase continuously 
with increasing urinary albumin levels, even after adjusting 
for numerous other factors (Basi and Lewis 2006). The 
pathophysiological process of albuminuria is not deﬁ  ni-
tively known, but may be related to endothelial dysfunction, 
inﬂ  ammation, and/or abnormalities in the renin-angiotensin-
aldosterone system; mechanisms that may be relevant in 
AFD but require further exploration. Interestingly, micro-
albuminuria (ie, 30–300 mg of albumin in a 24-hour urine 
collection) has been associated with other markers of vascular 
dysfunction, such as increased intima-media thickness; the 
latter a ﬁ  nding described in AFD patients, but whose pre-
dictive value remains to be established (Barbey et al 2006; 
Bigazzi 1995).
In the recently reported phase IIIB\IV placebo-controlled 
study involving agalsidase beta, a statistically signiﬁ  cant 
difference in composite primary endpoint (ie, worsening of 
kidney function, myocardial infarction, stroke or death) in 
favor of enzyme therapy was seen, only when the patients 
were stratiﬁ  ed by baseline proteinuria (in a per-protocol 
analysis) (Banikazemi et al 2007). On the other hand, those 
with more severe disease and proteinuria did not exhibit the 
same beneﬁ  ts. These observations were similar to that seen 
for a subset of patients (N = 6) in the original agalsidase-beta 
phase III who initially had well-preserved GFR values and 
overt proteinuria and went on to show a continuing decline of 
their kidney function at a rate that approached −10 ml/min per 
1.73 m2/year (Germain et al 2007). The predictive value of 
baseline proteinuria in AFD requires further investigation. In 
IgA nephropathy, baseline proteinuria was not signiﬁ  cantly 
related to renal progression; nor was hypertension or impaired 
renal function at onset (Coppo and D’Amico 2005). On the 
other hand, a multivariate Cox analysis revealed age and 
mean proteinuria during follow-up were powerful indepen-
dent prognostic predictors. Interestingly, IgA nephropathy in 
patients with AFD has been described (Whybra et al 2006). 
A comparative analysis of these patients may provide some 
insight into relevant prognostic factors.
Expert opinion
On ﬁ  nal analysis, the value of enzyme therapy for AFD will 
be judged based on its effectiveness in leading to a normal 
(event-free) survival and sustained improvement of patient 
health-related quality of life. Such an outcome would trans-
late into healthcare cost-savings from reduction in resource 
utilization (eg, dialysis, cardiac or renal transplant, stroke 
rehabilitation), along with contributions made during a 
productive life by affected individuals (with deferment of 
disability or death). These represent our therapeutic goals; 
however, at the moment we should focus on examining the 
factors that inﬂ  uence treatment response, and the identiﬁ  ca-
tion of clinical markers that may be useful in projecting 
disease trajectory and individualizing the therapeutic regi-
men. We need to devise a staging system to stratify patients’ 
by disease state. This may entail a combination of clinical 
evaluations (eg, of endurance and cardiopulmonary function 
with the 6-minute walk test), imaging (eg, cardiac MRI to 
ascertain areas of ﬁ  brosis) and the histological characteriza-
tion of major target organs (such as the heart and kidney); 
during this initial period post introduction of enzyme therapy. 
Of particular importance is the need, on ﬁ  rst principle, to 
demonstrate that signiﬁ  cant Gb3 deposits are cleared from 
other cells types and not just endothelium. This concern is 
highlighted by two recent reports that examined cardiac 
myocyte in two patients treated with agalsidase beta. In 
one patient, a 47-year-old man treated for about 2.5 years, 
numerous lamellar inclusions were found in cardiac myocytes 
(Schiffmann et al 2006). In the other patient, a 51-year-old 
male who received agalsidase beta for over 18 months, 
light microscopy revealed glycolipid storage typical for 
untreated AFD. Although the cardiac myocytes did not 
show the typical lamellar inclusions there were extensive Biologics: Targets & Therapy 2007:1(3) 298
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aggregates and single tubular crystalline structures, giant 
secondary lysosomes (5–6 μm) as well as abnormal branched 
chain glycogen (Owens et al 2006). These observations are 
particularly fascinating as there are patients with AFD who 
exhibit residual enzyme activity with a restricted phenotype, 
in which cardiac involvement represents the predominant 
feature. Thus, cardiac muscle may not be sufﬁ  ciently targeted 
by exogenous enzyme, or heart involvement may be a feature 
of AFD requiring prolonged treatment to show a response. 
There are no comparable studies in agalsidase alfa-treated 
patients; thus, it is not certain whether therapeutic outcome 
may be different in such treated individuals.
The majority of reported studies have described the treat-
ment outcome in the adult male with AFD. As a subset of 
these treated patients remain symptomatic and show disease 
progression, several investigators have argued in favor of 
starting treatment earlier (ie, in childhood or juvenile period). 
This contention appears to be supported by the recent head 
to head trial, in which treatment failure was not observed in 
the AFD patients younger than 40 years and with a disease 
severity score 17 (Vedder et al 2007). Similarly, the treat-
ment of symptomatic females has also gained favor as the 
burden of disease among heterozygotes has clearly been 
underestimated until recently (Eng et al 2007). The major 
issues in this regard, are at what age and which women; as 
the cumulative direct and indirect cost of treatment would be 
high and could involve risks related to infusion reactions.
The systemic nature of AFD necessitates a multimodal-
ity approach that integrates adjunctive therapies. A chief 
predicament in interpreting outcome data and determining 
the scope of treatment effect(s) from enzyme therapy lies in 
the fact that therapeutic responses are presented for each of the 
major organs (kidney, heart and brain) for cohorts of patients 
in relative isolation; that is, with a paucity of information on 
co-existing problems. This issue may be partly addressed by 
utilizing a staging system that allows for the stratiﬁ  cation of 
patients by disease severity at baseline. For instance, stratify-
ing patients according to baseline by age and renal function 
may provide a better insight regarding overall therapeutic 
response proﬁ  le. In a prospective, open-label study involving 
26 patients (with one early death), impaired renal function 
(ie, GFR 60 mL/min) was associated with a less favorable 
outcome and greater risk for developing cardiovascular and 
renal end points (Breunig et al 2006). Furthermore, most 
of the current reports do not provide data on the types (and 
doses) of adjunctive agents that are used. Thus, a complete 
analysis of the effectiveness of enzyme therapy will have 
to take into account the use of these other medications that 
may inﬂ  uence outcome. At the moment, based on currently 
available clinical outcomes data and taking into account the 
outlay in healthcare dollars for enzyme therapy, to declare 
that this option represents an unqualiﬁ  ed treatment advance 
for symptomatic AFD requires a leap of faith.
Summary
Regulatory approval for the use of agalsidase alfa in patients 
with AFD has been granted within the member states of the 
European Union. There is increasing evidence to support 
claims for its safety and disease modifying effects; leading to 
its greater use, which includes administration within the home 
setting. Although the bulk of treatment experience is with 
the use of an enzyme dose of 0.2 mg/kg every other week, 
further studies are required to deﬁ  ne the optimal treatment 
regimen (ie, enzyme dose and frequency of administration) 
for the individual patient.
Concerns have been raised regarding the cost of ERT, 
as estimations indicate a perpetual net deﬁ  cit to society 
under current costing and ERT efﬁ  cacy as determined by 
the QALY metric (Moore et al 2007). Thus, it has been sug-
gested that rules of fair cooperation should govern decision 
making both for ERT in AFD and for funding therapeutic 
advances in other rare diseases belonging to the orphan and 
ultra-orphan categories.
Management issues which remain outstanding include 
the following: (1) the inability to assign disease stage for 
the purposes of prognostication and determination of the 
appropriate time to intervene, (2) uncertainty regarding the 
repertoire of clinical investigations and diagnostic modalities 
to establish pretreatment disease severity, (3) the optimal 
regimen individualized to the patient’s current disease status, 
and (4) the combination of adjunctive therapies that may be 
useful in the primary and secondary prevention of adverse 
outcomes. There is an active search for surrogate markers, 
which may lead to greater understanding of pathogenesis and 
the identiﬁ  cation of rational therapeutic targets. There is a 
pressing need to focus on the assessment of the true beneﬁ  t 
from enzyme therapy, in terms of event-free survival and 
patient health-related quality of life. Medical practice in the 
specialized ﬁ  eld of AFD demands an expanded model of 
partnerships, involving healthcare providers, biotechnology 
companies, third party payers and healthcare policy makers; 
to ensure delivery of the most advantageous and high quality 
patient care. The current organizational culture drives col-
laborative relationships, with therapeutic guidelines from key 
opinion-leaders, based primarily on data derived from obser-
vational databases or open-label studies, mostly conducted Biologics: Targets & Therapy 2007:1(3) 299
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under the auspices of industry; clearly transparency is crucial. 
After almost a decade of clinical investigation, one would 
hope to have achieved several major therapeutic milestones, 
or at least a signiﬁ  cant inroad in the care of AFD patients. 
Verily, we still are at the beginning of our journey towards 
better health for patients.
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